Post-hoc analysis of clinical trial results by Raison et al. (2013) demonstrated that persons with treatment-resistant depression and high baseline CRP (>5 mg/L) exhibited a higher rate of treatment response (62 vs. 33%) when administered infliximab as compared to a placebo-treated group. The gene discussed is CRP; the disease is depressive symptom measurement.